Techniques in Vascular & Interventional Radiology
Volume 9, Issue 2 , Pages 56-63 , June 2006

Monitoring Antiplatelet Therapy During Peripheral Vascular and Coronary Interventions

  • Ehtisham Mahmud, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ehtisham Mahmud, MD, FACC, Director, Cardiovascular Catheterization Laboratory, UCSD Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8784.
    • ,
  • Lawrence Ang, BS

References 

  1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  2. Nguyen TA, Diodati JG, Pharand C. Resistance to Clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45:1157–1164
  3. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489–e493
  4. Han J, Lim CW, Watanabe N, et al. Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3. Curr Biol. 2006;16:1796–1806
  5. Born GVR. Aggregation of blood platelets by adenosine and its reversal. Nature. 1962;194:927–929
  6. O’Brien JR. Platelet aggregation Part II: some results of a new method. J Clin Pathol. 1962;15:452–455
  7. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. Am J Cardiol. 2006;98:S4–S10
  8. Michelson AD, Cattaneo M, Eidelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309–1311
  9. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke. 2005;36:1001–1005
  10. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004;35:175–178
  11. Hezard N, Metz D, Mazeyrollas P, et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost. 2000;83:540–544
  12. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J. 2001;141:226–233
  13. Madan M, Berkowitz SD, Christie DJ, et al. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J. 2002;144:151–158
  14. Hayward CPM, Harrison P, Cattaneos M, et al. Platelet function Analyzer (PFA-100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:1433–1434
  15. Malanin AI, Spergling M, Muhlestein B, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis. 2004;15:295–301
  16. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23:349–356
  17. Antithrombitic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  18. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360
  19. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention—Clopidogrel in Unstable Angina to prevent Recurrent Events (PCI-CURE) Study: a US perspective. Circulation. 2002;106:2284
  20. Cairns JA, Gent M, Singer J, et al. Aspirin, Sulfinpyrazone, or both in unstable angina (Results of a Canadian multicenter trial). N Engl J Med. 1985;313:1369–1375
  21. The Risk Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830
  22. Steinhubl SR, Berger PB, Mann JT, et al. Credo Investigators Clopidogrel for the reduction of events during observation. JAMA. 2003;289:1926–1927
  23. Fox KA, Mehta SR, Peters R, et al. Clopidogrel in unstable angina to prevent recurrent ischemic events trial. Circulation. 2004;110:1202–1208
  24. Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlodipine and aspirin after the placement of coronary-artery stents. Circulation. 2000;101:590–593
  25. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology American Heart Association Committee on the Management of Patients with Unstable Angina ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  26. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112:2946–2950
  27. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2005;111:2099–2106
  28. Montalescot G, Sideris G, Meuleman C, et al. ALBION Trial Investigators A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931–938
  29. Kastrati A, Mehilli J, Neumann FJ, et al. Intracoronary Stenting and Antithrombotic Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. JAMA. 2006;295:1531–1538
  30. Markus KS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111:2233–2240
  31. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:609S–626S
  32. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  33. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation). N Engl J Med. 2001;345:494–502
  34. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombic events. N Engl J Med. 2006;354:1706–1717
  35. Brener SJ, Barr LA, Burchenal , et al. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734–741
  36. Montalescot G, Barragan P, Wittenberg O, et al. ADMIRAL Investigators Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up (Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction). N Engl J Med. 2001;344:1895–1903
  37. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915–921
  38. Stone GW, Grines CL, Cox DA, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators (Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction). N Engl J Med. 2002;346:957–966
  39. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109:1704–1706
  40. Moser M, Bertram U, Peter K, et al. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol. 2003;41:586–592
  41. Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation. 2002;105:2347–2354
  42. Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol. 2002;89:1452
  43. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103:2572–2578
  44. Rocha-Singh KJ, Rutherford J. Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial. Catheter Cardiovasc Interv. 2005;66:470–473
  45. Allie DE, Hebert CJ, Lirtzman MD, et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol. 2005;17:427–432
  46. Wholey MH, Wholey MH, Eles G, et al. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther. 2003;10:33–41
  47. Barkhoudarian G, Ali MJ, Deveikis J, Thompsom BG. Intravenously administered abciximab in the management of early cerebral ischemia after carotid endarterectomy: case report. Neurosurgery. 2004;55:709
  48. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients (Evidence of nonresponders in a subpopulation of treated patients). Thromb Res. 1991;63:587–593
  49. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002;252:233–238
  50. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246–251
  51. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk Assessment (VERITAS) study. Thromb Res. 2007;119:277–284
  52. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122–1126
  53. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742–1750
  54. Kastrati A, Schuhlen H, Hausleiter J, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997;96:462–467
  55. Chaturvedi S, Yadav JS. The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke. 2006;37:1572–1577
  56. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553–1559
  57. Steinhubl SR. The VerifyNow System. In:  Michelson AD editors. Platelets. (ed 2). San Diego, CA: Elsevier/Academic Press; 2006;p. 509–518
  58. Steinhubl SR, Kereiakes DJ. Ultegra rapid platelet function analyzer. In:  Michelson AD editors. Platelets. New York, NY: Academic Press/Elsevier Science; 2002;p. 317–324

 Support for Lawrence Ang was provided in part by the UCSD SMART (SIRA Medical–Student Aging Research Training) grant.

PII: S1089-2516(06)00050-3

doi: 10.1053/j.tvir.2006.12.006

Techniques in Vascular & Interventional Radiology
Volume 9, Issue 2 , Pages 56-63 , June 2006

Article Tools

* Image Usage & Resolution